Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113105283 | 11310528 | 3 | F | 201506 | 20160824 | 20150724 | 20160902 | EXP | US-009507513-1507USA008215 | MERCK | 72.00 | YR | M | Y | 145.00000 | KG | 20160902 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113105283 | 11310528 | 1 | PS | COZAAR | LOSARTAN POTASSIUM | 1 | Oral | 100 MG, QD | Y | U | 20386 | 100 | MG | TABLET | QD | ||||
| 113105283 | 11310528 | 2 | SS | COZAAR | LOSARTAN POTASSIUM | 1 | Oral | 100 MG, QD | Y | U | 20386 | 100 | MG | TABLET | QD | ||||
| 113105283 | 11310528 | 3 | SS | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Oral | 25 MG, QD | Y | 0 | 25 | MG | TABLET | QD | |||||
| 113105283 | 11310528 | 4 | SS | LOPRESSOR | METOPROLOL TARTRATE | 1 | Oral | 25 MG, BID | U | N | 0 | 25 | MG | TABLET | BID | ||||
| 113105283 | 11310528 | 5 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 81 MG, BID | U | 0 | 81 | MG | TABLET | BID | |||||
| 113105283 | 11310528 | 6 | C | PROZAC | FLUOXETINE HYDROCHLORIDE | 1 | Oral | 20 MG, QD | U | 0 | 20 | MG | CAPSULE | QD | |||||
| 113105283 | 11310528 | 7 | C | GLUCOTROL | GLIPIZIDE | 1 | Oral | 5 MG, QD | U | 0 | 5 | MG | TABLET | QD | |||||
| 113105283 | 11310528 | 8 | C | PRILOSEC | OMEPRAZOLE MAGNESIUM | 1 | Oral | 20 MG, BID | U | 0 | 20 | MG | CAPSULE | BID | |||||
| 113105283 | 11310528 | 9 | C | DESYREL | TRAZODONE HYDROCHLORIDE | 1 | Oral | 20 MG, BID (HALF TABLET) | U | 0 | 20 | MG | TABLET | BID | |||||
| 113105283 | 11310528 | 10 | C | ATORVASTATIN | ATORVASTATIN | 1 | 80 MG, UNK | U | 0 | 80 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 113105283 | 11310528 | 1 | Hypertension |
| 113105283 | 11310528 | 3 | Hypertension |
| 113105283 | 11310528 | 4 | Hypertension |
| 113105283 | 11310528 | 5 | Cardiovascular event prophylaxis |
| 113105283 | 11310528 | 6 | Depression |
| 113105283 | 11310528 | 7 | Diabetes mellitus |
| 113105283 | 11310528 | 8 | Gastrooesophageal reflux disease |
| 113105283 | 11310528 | 9 | Depression |
| 113105283 | 11310528 | 10 | Hyperlipidaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 113105283 | 11310528 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 113105283 | 11310528 | Dizziness | |
| 113105283 | 11310528 | Hypotension | |
| 113105283 | 11310528 | Syncope |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 113105283 | 11310528 | 1 | 2004 | 20150604 | 0 | |
| 113105283 | 11310528 | 2 | 201506 | 0 | ||
| 113105283 | 11310528 | 3 | 2004 | 20150605 | 0 | |
| 113105283 | 11310528 | 4 | 2004 | 20150604 | 0 | |
| 113105283 | 11310528 | 5 | 2004 | 0 | ||
| 113105283 | 11310528 | 6 | 20141007 | 0 | ||
| 113105283 | 11310528 | 7 | 2004 | 0 | ||
| 113105283 | 11310528 | 8 | 2004 | 0 | ||
| 113105283 | 11310528 | 9 | 2010 | 0 | ||
| 113105283 | 11310528 | 10 | 2004 | 0 |